ToxSci Advance Access originally published online on June 7, 2006
Toxicological Sciences 2006 93(1):180-188; doi:10.1093/toxsci/kfl034
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Methoxychlor Metabolites May Cause Ovarian Toxicity Through Estrogen-Regulated Pathways
Program in Toxicology and Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201
1 To whom correspondence should be addressed at Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, 660 W. Redwood Street, Howard Hall Suite 133, Baltimore, MD 21201. Fax: (410) 706-1503. E-mail: jflaws{at}epi.umaryland.edu.
Received March 23, 2006; accepted June 5, 2006
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The pesticide methoxychlor (MXC) is a reproductive toxicant that targets antral follicles of the mammalian ovary. Cytochrome P450 enzymes metabolize MXC to mono-OH MXC (1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane [mono-OH]) and bis-OH MXC (1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane [HPTE]), two compounds that are proposed to be more toxic than the parent compound, can interact with the estrogen receptor (ER), and are proposed to be responsible for ovarian toxicity. Thus, this work tested the hypothesis that MXC metabolites may be responsible for inducing antral follicle–specific toxicities in the ovary and that this toxicity may be mediated through ER-regulated pathways. Mouse antral follicles were isolated and exposed to mono-OH (0.01–10 µg/ml), HPTE (0.01–10 µg/ml), or MXC (100 µg/ml) alone or in combination with ICI 182,780 (ICI; 1µM) or 17ß-estradiol (E2; 10 and 50nM) for 96 h. Follicle diameters were measured at 24-h intervals. After culture, follicles were morphologically evaluated for atresia. Both mono-OH and HPTE (10 µg/ml) inhibited follicle growth and increased follicle atresia. The antiestrogen, ICI, did not protect antral follicles from MXC or metabolite toxicity in regard to follicle growth or atresia, but E2 decreased MXC- and mono-OH–induced atresia in small antral follicles. These data suggest that MXC metabolites inhibit follicle growth and induce atresia and that ER-regulated pathways may mediate the ovarian toxicity of MXC and its metabolites.
Key Words: methoxychlor; metabolites; antral follicles; ovary; ICI 182,780; estradiol.
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The endocrine-disrupting chemical methoxychlor (MXC) is a widely used chlorinated organic pesticide (Cummings, 1997
) that targets the ovary, with outcomes including reduced fertility (Cummings and Gray, 1989; Swartz and Eroschenko, 1998) and follicular atresia (Martinez and Swartz, 1991; Swartz and Corkern, 1992). In vivo exposure of female mice to MXC results in antral follicle–specific toxicity characterized by a decreased number of healthy antral follicles and an increased percentage of atretic antral follicles versus controls (Borgeest et al., 2002). In vitro exposure of antral follicles to MXC also increases atresia, as well as inhibits antral follicle growth in culture (Miller et al., 2005). Damage to the antral follicle population is significant as it could result in reduced fertility and early reproductive senescence. In addition, antral follicles are responsible for synthesizing steroid hormones (estrogens, androgens, and progesterones); therefore, injury to this follicle population might impede hormone secretion, result in atypical hormone levels, and cause abnormal cyclicity.
Metabolites of MXC have been proposed to be more toxic than the parent compound and may be responsible for ovarian toxicity since MXC is readily metabolized in the body. Through cytochrome P450 (CYP) metabolism, MXC is metabolized to the predominant metabolites 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane (mono-OH) and 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane (HPTE) (Kapoor et al., 1970). These polar metabolites are thought to induce the endocrine-disrupting capabilities of MXC and mediate its estrogenic activity. Many investigations have focused on the ability of MXC and HPTE to bind to estrogen receptors (ER) 
and ß to act as endocrine disruptors. MXC, mono-OH, and HPTE have all been shown to compete with 17ß-estradiol (E2) for binding to ER to varying degrees; MXC has very low affinity for ER, while mono-OH and HPTE have higher affinity for ER (Bulger et al., 1978, 1985; Laws et al., 2000; Ousterhout et al., 1981). Both mono-OH and HPTE have been shown to be ER agonists and ERß antagonists (Gaido et al., 1999, 2000), though they are much less potent than E2 as ER agonists. Studies have shown that in the ovary, MXC acts as an estrogen antagonist (Hall et al., 1997) likely since ERß levels are higher than ER levels in this tissue (Gaido et al., 1999; Saunders et al., 1997). It is possible that the metabolites follow the same mechanism in the ovary as well, but this has not been tested.
Since MXC is readily metabolized in the body and MXC metabolites have been shown to be more potent as endocrine-disrupting chemicals than the parent compound, we hypothesized that MXC metabolites may be responsible for inducing antral follicle–specific toxicities in the ovary and that this toxicity may be mediated through ER-regulated pathways. Using an in vitro follicle culture assay, we exposed antral follicles to dose-response concentrations of mono-OH and HPTE and evaluated follicle growth and atresia. In addition, we investigated the potential role of ER in mediating the toxicity of MXC and its metabolites in antral follicles through cotreatment with the antiestrogen ICI 182,780 (ICI) to block the effect of these chemicals and protect against the chemically induced follicle growth inhibition and atresia, or cotreatment with E2 to observe whether the added E2 would override the toxicity of MXC and its metabolites and support follicle growth and cell survival. Our results show that MXC metabolites do have a toxic effect on antral follicle growth and atresia and that E2 regulation of ER pathways may play a role in mediating the ovarian toxicity of MXC and its metabolites.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Chemicals.
MXC (99% pure) was purchased from ChemService (West Chester, PA). Mono-OH and HPTE were purchased from Cedra Corporation (Austin, TX). Stock solutions of MXC, mono-OH, and HPTE for in vitro dosing were prepared using dimethylsulfoxide (DMSO) (Sigma, St Louis, MO) as a solvent and in various concentrations (133, 13.3, 1.33, 0.133, and 0.0133 mg/ml) that allowed an equal volume to be added to culture wells for each treatment group to control for solvent concentration. Final concentrations of MXC, mono-OH, and HPTE in culture were 100, 10, 1, 0.1, and 0.01 µg/ml (ppm). These doses were selected for in vitro studies because they have been shown to affect proliferation and gene expression in ovarian cells and uterine leiomyoma cells (Chedrese and Feyles, 2001
; Hodges et al., 2000). In addition, we have observed that MXC causes antral follicle atresia in vivo at concentrations of 32 and 64 mg/kg/day (32 and 64 ppm/day), 10 and 100 µg/ml MXC compromises follicle growth in culture, and 100 µg/ml MXC causes antral follicle atresia in culture (Borgeest et al., 2002, 2004; Miller et al., 2005). The selected in vitro doses are in the same range as the previously used in vivo doses. The in vitro doses are also environmentally relevant in that environmental levels of MXC range from 40–160 ppm in waters downstream of MXC-sprayed areas (Wallner et al., 1969) to 0.1–4.0 ppb/day exposures of humans via the diet (Agency for Toxic Substances and Disease Registry, 2002). ICI was obtained from Tocris-Cookson (Ellisville, MO). Stock solutions of ICI were prepared in DMSO (2mM) for a final dose in culture of 1µM. E2 was obtained from Sigma. Stock solutions of E2 were prepared in DMSO (20 or 100µM) for a final dose in culture of 10 or 50nM. Concentrations of ICI and E2 were chosen based on dose-response evaluations performed in our laboratory (Symonds et al., 2006; Barnett and Flaws, unpublished results). Unless otherwise specified, all reagents were obtained from Sigma.
Animals.
Female mice in a FVB background were used from breeding colonies currently maintained by our laboratory at the University of Maryland Central Animal Facility. Mice were housed (five animals per cage) at the University of Maryland Central Animal Facility and provided food and water ad libitum. Temperature was maintained at 22 ± 1°C, and animals were subjected to 12L:12D cycles. The University of Maryland School of Medicine Institutional Animal Use and Care Committee approved all procedures involving animal care, euthanasia, and tissue collection.
Follicle culture.
Female mice were sacrificed on postnatal days 30–35 and their ovaries removed. Antral follicles were isolated mechanically from the ovary based on relative size and cleaned of interstitial tissue using fine watchmaker forceps. Sufficient numbers of antral follicles for experimental significance were isolated from unprimed mouse ovaries; follicles from 2–4 mice were isolated per day with approximately 20–25 antral follicles from each mouse. Upon isolation, follicles were placed individually in wells of a 96-well culture plate with unsupplemented -minimal essential media (-MEM) prior to treatment. Each experiment contained a minimum of eight follicles per treatment. Supplemented -MEM was prepared with 1% ITS (10 ng/ml insulin, 5.5 ng/ml transferrin, 5.5 ng/ml selenium), 100 U/ml penicillin, 100 mg/ml streptomycin, 5 IU/ml human recombinant Follicle-stimulating hormone (Dr A. F. Parlow, National Hormone and Peptide Program, Harbor-UCLA Medical Center, Torrance, CA), and 5% fetal calf serum (Atlanta Biologicals, Lawrenceville, GA). A dose-response regimen of mono-OH (0.01–10 µg/ml), HPTE (0.01–10 µg/ml), and DMSO controls was individually prepared in supplemented -MEM with an equal volume of chemical added for each dose to control for the amount of vehicle in each preparation. For cotreatment experiments, ICI (1µM) or E2 (10 or 50nM) was prepared alone and in combination with MXC (100 µg/ml), mono-OH (10 µg/ml), or HPTE (10 µg/ml) in supplemented -MEM. For treatment, unsupplemented -MEM was removed from each well and replaced with 150 µl supplemented -MEM containing vehicle or chemicals of interest. Follicles were then incubated for 0–96 h at 37°C in 95% air and 5% CO2. DMSO concentrations in all experiments were kept below 0.075% for dose-response follicle growth experiments and less than 0.125% for coincubation experiments using ICI and E2. These are levels that solubilized MXC, mono-OH, and HPTE in aqueous media without overt changes in growth or atresia.
Analysis of follicle growth.
Antral follicles were cultured as described above for 96 h. Follicle growth was examined at 24-h intervals by measuring follicle diameter on two perpendicular axes with an inverted microscope equipped with a calibrated ocular micrometer. Antral follicles were considered as those having diameters of 200 µm or greater (Smitz and Cortvrindt, 2002), which correlates with the histological appearance of these follicles. At least three separate culture experiments were performed for each chemical treatment. Follicle diameter measurements were averaged among treatment groups and plotted to compare the effects of chemical treatments on growth over time.
Histological evaluation of atresia.
At the end of each follicle culture, supplemented -MEM was removed from each well and Dietrick's solution was immediately added to fix follicles. Follicles were fixed for at least 24 h in Dietrick's solution and transferred in histology cassettes to 70% ethanol. The tissues were dehydrated, embedded in Paraplast (VWR Scientific, West Chester, PA), serially sectioned (5 µm), mounted on glass slides, and stained with Weigert's hematoxylin and methyl blue:picric acid. Each follicle section was examined for level of atresia as evidenced by the presence of pyknotic bodies and reported at the highest level observed throughout the tissue. Follicles were rated on a scale of 1–5 for the presence of pyknotic bodies: 1 = healthy; 2 = less than 10% pyknotic bodies (early); 3 = 10–30% pyknotic bodies (mid); 4 = greater than 30% pyknotic bodies in an isolated area (late); and 5 = greater than 30% pyknotic bodies over the entire follicle (late and widespread). Representative photographs of atresia ratings have been previously published (Miller et al., 2005). In addition, follicles were evaluated based on size: small follicles (200–349 µm starting diameter) versus large follicles (350 µm and larger starting diameter). This was done to compare atresia in small and large follicles in response to MXC because studies indicate that small and large antral follicles may respond differently to toxicants (Hirshfield, 1988; Roby, 2001). At least three separate culture experiments and atresia analyses were performed for each chemical treatment. Ratings were averaged and plotted to compare the effect of chemical treatments on atresia levels.
Statistical analysis.
All data were analyzed using SPSS statistical software (SPSS Inc., Chicago, IL). For all comparisons, statistical significance was assigned at p 
0.05. For multiple comparisons between DMSO and MXC-, mono-OH-, and HPTE-treated follicles and E2- or ICI-cotreated follicles, we used analysis of variance, along with a Tukey post hoc test, multiple regression analysis, or Mann-Whitney nonparametric tests. At least eight follicles per treatment per growth experiment were evaluated, and the results of at least three separate experiments were combined for data analysis.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Exposure of mouse antral follicles in vitro to MXC (10 and 100 µg/ml) has been shown to inhibit follicle growth after 72 and 96 h in culture and increase atresia over control levels after 96 h in culture (Miller et al., 2005
). To investigate whether metabolites of MXC would induce the same toxicities, we exposed antral follicles in vitro to either mono-OH or HPTE (0.01–10 µg/ml) and evaluated their growth over time and resulting atresia. Mono-OH significantly inhibited antral follicle growth over control levels at both 72 and 96 h after exposure (Fig. 1A). In addition, mono-OH (10 µg/ml) increased atresia of small and large antral follicles over control levels (Figs. 1B and 1C). HPTE (10 µg/ml) only inhibited antral follicle growth at 96 h postexposure (Fig. 2A) and increased atresia in small antral follicles but not large antral follicles (Figs. 2B and 2C).
|
|
To determine whether MXC or its metabolites induce toxicity in antral follicles via an ER-regulated mechanism, we cotreated antral follicles in culture with the antiestrogen ICI (1µM) or E2 (10 or 50nM) and MXC (100 µg/ml), mono-OH (10 µg/ml), or HPTE (10 µg/ml) and evaluated follicle growth and atresia. Antral follicles treated with ICI alone grew in culture in a manner similar to controls; however, ICI cotreatment with MXC, mono-OH, or HPTE did not reverse the growth inhibition due to MXC, mono-OH, or HPTE and still inhibited follicle growth without any significant difference from chemical alone at all time points examined (0–96 h) (Figs. 3A–3C). As for atresia, ICI alone did not induce atresia over controls in either small or large antral follicles and levels remained comparable to DMSO (Figs. 4A–4F). ICI cotreatment with MXC or mono-OH did not change the levels of follicle atresia in either small or large antral follicles compared to atresia levels with chemical alone.
|
|
Antral follicles treated with E2 alone (10 and 50nM) grew in culture in a manner similar to controls, however, E2 cotreatment with MXC, mono-OH, or HPTE was not sufficient to reverse the growth inhibition due to MXC, mono-OH, or HPTE and still inhibited follicle growth without any significant difference from chemical alone at all time points examined (0–96 h) (Figs. 5A–5C). E2 (10nM) was able, however, to reduce the amount of atresia induced by MXC in small antral follicles after 96 h and, at a concentration of 50nM, was able to reduce the amount of atresia induced by mono-OH in small antral follicles after 96 h (Figs. 6A and 6C). E2 did not have any effect on the amount of atresia induced by HPTE in these experiments (Figs. 6E and 6F).
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
The present studies were conducted to test the hypothesis that MXC metabolites may be responsible for inducing antral follicle–specific toxicities in the ovary and that this toxicity may be mediated through ER-regulated pathways. To begin, we have shown that the MXC metabolites mono-OH and HPTE are both directly toxic to antral follicles, similar to the toxicity found with the parent compound (Miller et al., 2005
). Mono-OH inhibits antral follicle growth to the same degree as MXC at both 72 and 96 h, while HPTE also inhibits antral follicle growth, but only after 96 h exposure. In addition, mono-OH induces atresia of small and large antral follicles in the same manner as MXC but at a lower concentration (10 µg/ml mono-OH vs. 100 µg/ml MXC), while HPTE (10 µg/ml) induces atresia of small antral follicles only. Therefore, one possible mechanism of MXC toxicity in the ovary could be through metabolism of the parent compound by the liver and/or ovary to these metabolites that would then cause toxicity.
While both metabolites cause antral follicle toxicity, our results indicate that mono-OH may be slightly more toxic than HPTE in our antral follicle culture system as follicle growth inhibition occurs at an earlier time point, and the rating of atresia in small antral follicles tended to be slightly higher with mono-OH exposure than HPTE. Specifically, HPTE 10 exposure only induces atresia in small antral follicles at ratings between 2.1 and 2.4, which indicate 10% pyknotic bodies or less, while mono-OH 10 induces atresia in this same population of follicles at ratings between 3.2 and 4.0, which indicate 10–30% or higher pyknotic bodies. Many studies have primarily focused on HPTE as the primary toxic metabolite of MXC (Bulger et al., 1978; Gaido et al., 1999, 2000; Waters et al., 2001); therefore, the finding that mono-OH may be more toxic than HPTE in our system is novel. HPTE has been shown to have a higher affinity for ER than mono-OH or MXC and has been primarily investigated as responsible for the endocrine-disrupting capabilities of MXC (Bulger et al., 1985; Gaido et al., 1999, 2000; Ousterhout et al., 1981). Studies by Ohyama et al. (2005), however, help to support our findings of the toxicity of mono-OH as they have shown that there is sex-specific metabolism of MXC. In rat liver slices, MXC is primarily metabolized to mono-OH versus HPTE in female rats (60/40 mono/bis ratio), while in male rats, MXC is primarily metabolized to HPTE versus mono-OH (5/95 mono/bis ratio). Female rodents may then be more susceptible to mono-OH toxicity since this is a primary metabolite formed upon MXC metabolism in the female rodent liver. Alternatively, many of the aforementioned studies with HPTE were performed in uterine tissue and HepG2 cells, possibly indicating tissue-specific toxicity of mono-OH versus HPTE. In a study by Waters et al. (2001), differential HPTE-regulated gene expression was observed in the uterus versus ovary. Therefore, it is possible that mono-OH may regulate genes with a greater effect than HPTE in the ovary.
MXC has been shown to be an ER agonist and ERß antagonist (Gaido et al., 1999, 2000), and HPTE has been shown to regulate a variety of genes through ER mechanisms (Waters et al., 2001). Therefore, we examined whether the inhibition of antral follicle growth and increase in atresia that we observe in antral follicles upon MXC and metabolite exposure were mediated by ER mechanisms and could be blocked by cotreatment with ICI or E2. The antiestrogen ICI was unable to protect antral follicles treated with MXC, mono-OH, or HPTE from decreased follicle growth in culture and was also unable to protect MXC- and mono-OH–exposed antral follicles from atresia. Thus, it appeared that the toxicity of MXC could not be reduced by an ER- or ERß-mediated mechanism. When antral follicles were cotreated with E2, along with MXC, mono-OH, or HPTE, there was no protection from decreased follicle growth in culture; however, E2 was able to protect MXC- and mono-OH–exposed small antral follicles from atresia. As a result, E2 is able to inhibit MXC and metabolite toxicity in small antral follicles, though the mechanism may not be ER dependent as we had initially hypothesized. It is important to note that we do not think that the metabolism of MXC is compromised in the presence of E2 as E2 does not significantly inhibit CYP activities in human liver microsomes exposed to MXC in culture (Laine et al., 2003). Moreover, treatment of male channel catfish with E2 does not affect the conversion of MXC to mono-OH or HPTE, indicating that E2 exerts its effect downstream of metabolism (Schlenk et al., 1997).
One possible mechanism of estrogen-regulated ER-independent MXC toxicity could involve E2 regulation of apoptotic pathways through nongenomic mechanisms. In support of this mechanism, MCF-7 breast cancer cells exposed to E2 showed increased levels of antiapoptotic Bcl-2 protein without any changes in apoptotic Bax protein levels (Kandouz et al., 1996). In addition, E2 has also been shown to phosphorylate cAMP response element–binding protein to then upregulate bcl-2 through a phosphatidyl inositol 3-kinase/Akt–dependent pathway (Honda et al., 2001). This is further supported by evidence that E2 regulation of bcl-2 gene expression does not require direct ER binding to the promoter region but involves E2-induced activation of cAMP (Dong et al., 1999). These nongenomic mechanisms of E2-regulating apoptotic signaling are highly likely since we have previously shown that overexpression of Bcl-2 in the ovary protects from MXC-induced growth inhibition and atresia in antral follicles (Miller et al., 2005). A second possible mechanism of toxicity through ER-independent pathways may be involved also in that E2 possesses antioxidant activity (Behl et al., 1995). E2 could be acting as an antioxidant to reduce cell injury and apoptosis caused by the generation of oxidative stress through MXC metabolism in the ovary (Latchoumycandane and Mathur, 2002).
In conclusion, these studies have shown that the MXC metabolites mono-OH and HPTE directly inhibit antral follicle growth and induce atresia, and that this toxicity may be mediated by estrogen-regulated pathways. Future studies to investigate the protection from MXC toxicity by nongenomic actions of E2 will be helpful in developing ways to prevent toxicity by similar environmental chemicals and preserve ovarian health and fertility.
|
ACKNOWLEDGMENTS |
|---|
The authors would like to acknowledge funding by NIH RO1 ES012893 [GenBank] , NIH R21 ES1306, T32 ES07263-13, and a Colgate-Palmolive Postdoctoral Fellowship in In Vitro Toxicology. In addition, the authors would like to thank Janice Babus for her assistance with histology and Lynn Lewis for her assistance with formatting the manuscript.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Agency for Toxic Substances and Disease Registry (2002). Toxicological Profile for Methoxychlor, pp. 161. U.S. Department of Health and Human Services Public Health Service, ATSDR, Atlanta, GA.
Behl, C., Widmann, M., Trapp, T., and Holsboer, F. (1995). 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem. Biophys. Res. Commun. 216, 473–482.[CrossRef][ISI][Medline]
Borgeest, C., Miller, K. P., Gupta, R., Greenfeld, C., Hruska, K. S., Hoyer, P. B., and Flaws, J. A. (2004). Methoxychlor-induced atresia in the mouse involves Bcl-2 family members, but not gonadotropins or estradiol. Biol. Reprod. 70, 1828–1835.
Borgeest, C., Symonds, D., Mayer, L. P., Hoyer, P. B., and Flaws, J. A. (2002). Methoxychlor may cause ovarian follicular atresia and proliferation of the ovarian epithelium in the mouse. Toxicol. Sci. 68, 473–478.
Bulger, W. H., Feil, V. J., and Kupfer, D. (1985). Role of hepatic monooxygenases in generating estrogenic metabolites from methoxychlor and from its identified contaminants. Mol. Pharmacol. 27, 115–124.[Abstract]
Bulger, W. H., Muccitelli, R. M., and Kupfer, D. (1978). Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites. Role of hepatic mono-oxygenase in methoxychlor activation. Biochem. Pharmacol. 27, 2417–2423.[CrossRef][ISI][Medline]
Chedrese, P. J., and Feyles, F. (2001). The diverse mechanism of action of dichlorodiphenyl-dichloroethylene (DDE) and methoxychlor in ovarian cells in vitro. Reprod. Toxicol. 15, 693–698.[CrossRef][ISI][Medline]
Cummings, A. M. (1997). Methoxychlor as a model for environmental estrogens. Crit. Rev. Toxicol. 27, 367–379.[ISI][Medline]
Cummings, A. M., and Gray, L. E., Jr. (1989). Antifertility effect of methoxychlor in female rats: Dose- and time-dependent blockade of pregnancy. Toxicol. Appl. Pharmacol. 97, 454–462.[CrossRef][ISI][Medline]
Dong, L., Wang, W., Wang, F., Stoner, M., Reed, J. C., Harigai, M., Samudio, I., Kladde, M. P., Vyhlidal, C., and Safe, S. (1999). Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J. Biol. Chem. 274, 32099–32107.
Gaido, K. W., Leonard, L. S., Maness, S. C., Hall, J. M., McDonnell, D. P, Saville, B., and Safe, S. (1999). Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors and ß. Endocrinology 140, 5746–5753.
Gaido, K. W., Maness, S. C., McDonnell, D. P, Dehal, S. S., Kupfer, D., and Safe, S. (2000). Interaction of methoxychlor and related compounds with estrogen receptor and ß, and androgen receptor: Structure activity studies. Mol. Pharmacol. 58, 852–858.
Hall, D. L., Payne, L. A., Putnam, J. M., and Huet-Hudson, Y. M. (1997). Effect of methoxychlor on implantation and embryo development in the mouse. Reprod. Toxicol. 11, 703–708.[CrossRef][ISI][Medline]
Hirshfield, A. N. (1988). Size-frequency analysis of atresia in cycling rats. Biol. Reprod. 38, 1181–1188.[Abstract]
Hodges, L. C., Bergerson, J. S., Hunter, D. S., and Walker, C. L. (2000). Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro. Toxicol. Sci. 54, 355–364.
Honda, K., Shimohama, S., Sawada, H., Kihara, T., Nakamizo, T., Shibasaki, H., and Akaike, A. (2001). Nongenomic antiapoptotic signal transduction by estrogen in cultured cortical neurons. J. Neurosci. Res. 64, 466–475.[CrossRef][ISI][Medline]
Kandouz, M., Siromachkova, M., Jacob, D., Chretien Marquet, B., Therwath, A., and Gompel, A. (1996). Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. Int. J. Cancer 68, 120–125.[CrossRef][ISI][Medline]
Kapoor, I. P., Metcalf, R. L., Nystrom, R. F., and Sangha, G. K. (1970). Comparative metabolism of methoxychlor, methiochlor, and DDT in mouse, insects, and in a model ecosystem. J. Agric. Food Chem. 18, 1145–1152.[CrossRef][ISI][Medline]
Laine, K., Yasar, U., Widen, J., and Tybring, G. (2003). A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol. Toxicol. 93, 77–81.[CrossRef][ISI][Medline]
Latchoumycandane, C., and Mathur, P. P. (2002). Induction of oxidative stress in the rat testis after short-term exposure to the organochlorine pesticide methoxychlor. Arch. Toxicol. 76, 692–698.[CrossRef][ISI][Medline]
Laws, S. C., Carey, S. A., Ferrell, J. M., Bodman, G. J., and Cooper, R. L. (2000). Estrogenic activity of octylphenol, nonylphenol, bisphenol A and methoxychlor in rats. Toxicol. Sci. 54, 154–167.
Martinez, E. M., and Swartz, W. J. (1991). Effects of methoxychlor on the reproductive system of the adult female mouse. 1. Gross and histologic observations. Reprod. Toxicol. 5, 139–147.[CrossRef][ISI][Medline]
Miller, K. P., Gupta, R. K., Greenfeld, C. R., Babus, J. K., and Flaws, J. A. (2005). Methoxychlor directly affects ovarian antral follicle growth and atresia through Bcl-2- and Bax-mediated pathways. Toxicol. Sci. 88, 213–221.
Ohyama, K., Maki, S., Sato, K., and Kato, Y. (2005). Comparative in vitro metabolism of the suspected pro-estrogenic compound, methoxychlor in precision-cut liver slices from male and female rats. Xenobiotica 35, 331–342.[CrossRef][ISI][Medline]
Ousterhout, J., Struck, R. F., and Nelson, J. A. (1981). Estrogenic activities on methoxychlor metabolites. Biochem. Pharmacol. 30, 2869–2871.[CrossRef][ISI][Medline]
Roby, K. F. (2001). Alterations in follicle development, steroidogenesis, and gonadotropin receptor binding in a model of ovulatory blockade. Endocrinology 142, 2328–2335.
Saunders, P. T., Maguire, S. M., Gaughan, J., and Millar, M. R. (1997). Expression of oestrogen receptor beta (ER beta) in multiple rat tissues visualized by immunohistochemistry. J. Endocrinol. 154, R13–R16.[Abstract]
Schlenk, D., Stresser, D. M., McCants, J. C., Nimrod, A. C., and Benson, W. H. (1997). Influence of beta-naphthoflavone and methoxychlor pretreatment on the biotransformation and estrogenic activity of methoxychlor in channel catfish (Ictalurus punctatus). Toxicol. Appl. Pharmacol. 145, 349–356.[CrossRef][ISI][Medline]
Smitz, J. E., and Cortvrindt, R. G. (2002). The earliest stages of folliculogenesis in vitro. Reproduction 123, 185–202.[Abstract]
Swartz, W. J., and Corkern, M. (1992). Effects of methoxychlor treatment of pregnant mice on female offspring of the treated and subsequent pregnancies. Reprod. Toxicol. 6, 431–437.[CrossRef][ISI][Medline]
Swartz, W. J., and Eroschenko, V. P. (1998). Neonatal exposure to technical methoxychlor alters pregnancy outcome in female mice. Reprod. Toxicol. 12, 565–573.[CrossRef][ISI][Medline]
Symonds, D. A., Miller, K. P., Tomic, D., and Flaws, J. A. (2006). Effect of methoxychlor and estradiol on cytochrome p450 enzymes in the mouse ovarian surface epithelium. Toxicol. Sci. 289, 510–514.
Wallner, W. E., Leeling, N. C., and Zabik, M. J. (1969). The fate of methoxychlor applied by helicopter for smaller European elm bark beetle control. J. Econ. Entomol. 62, 1039–1042.
Waters, K. M., Safe, S., and Gaido, K. W. (2001). Differential gene expression in response to methoxychlor and estradiol through ER, ERß, and AR in reproductive tissues of female mice. Toxicol. Sci. 63, 47–56.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Symonds, I. Merchenthaler, and J. A. Flaws Methoxychlor and Estradiol Induce Oxidative Stress DNA Damage in the Mouse Ovarian Surface Epithelium Toxicol. Sci., September 1, 2008; 105(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rasier, A.-S. Parent, A. Gerard, R. Denooz, M.-C. Lebrethon, C. Charlier, and J.-P. Bourguignon Mechanisms of Interaction of Endocrine-Disrupting Chemicals with Glutamate-Evoked Secretion of Gonadotropin-Releasing Hormone Toxicol. Sci., March 1, 2008; 102(1): 33 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Gupta, G. Aberdeen, J. K. Babus, E. D. Albrecht, and Jodi. A. Flaws Methoxychlor and Its Metabolites Inhibit Growth and Induce Atresia of Baboon Antral Follicles Toxicol Pathol, August 1, 2007; 35(5): 649 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Uzumcu, P. E Kuhn, J. E Marano, A. E Armenti, and L. Passantino Early postnatal methoxychlor exposure inhibits folliculogenesis and stimulates anti-Mullerian hormone production in the rat ovary J. Endocrinol., December 1, 2006; 191(3): 549 - 558. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||